Skip to main content

Table 1 Baseline characteristics and surgical procedures

From: Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase II randomized controlled trial

 

Control (n = 15)

Low Dose (n = 15)

High Dose (n = 15)

Total (n = 45)

Age (years) (mean, SD)

55.5 (15.3)

57.5 (13.2)

53.8 (9.9)

55.6 (12.8)

Surgery Type (N, %)

 Lumpectomy

10 (66.7)

9 (60.0)

10 (66.7)

29 (64.4)

 Mastectomy

5 (33.3)

6 (37.5)

5 (33.3)

16 (35.5)

Diagnosis (N, %)

 IDC

13 (86.7)

13 (86.7)

11 (73.3)

37 (82.2)

 ILC

1 (6.7)

2 (13.3)

4 (26.7)

7 (15.6)

 IMC

1 (6.7)

0 (0.0)

0 (0.0)

1 (6.7)

Primary Tumour Size (cm) (mean, SD)

3.1 (1.2)

2.7 (0.9)

3.3 (2.2)

3.0 (1.5)

Grade (N, %)

 1

1 (6.7)

1 (6.7)

1 (6.7)

3 (6.7)

 2

4 (26.6)

6 (40.0)

5 (33.3)

15 (33.3)

 3

10 (66.7)

8 (53.3)

9 (60.0)

27 (60.0)

Mitotic Score (N, %)

 1

4 (26.7)

5 (33.3)

5 (33.3)

14 (31.1)

 2

3 (20.0)

3 (20.0)

4 (26.7)

10 (22.2)

 3

8 (53.3)

7 (46.7)

6 (37.5)

21 (46.7)

ER Status (N, %)

 Positive

12 (80.0)

12 (80.0)

11 (73.3)

35 (77.8)

 Negative

3 (20.0)

3 (20.0)

4 (26.7)

10 (22.2)

PR Status (N, %)

 Positive

12 (80.0)

10 (66.7)

10 (66.7)

32 (71.1)

 Negative

3 (20.0)

5 (33.3)

5 (33.3)

13 (28.9)

Her2 Status (N, %)

 Positive

1 (6.7)

4 (26.7)

2 (13.3)

7 (15.6)

 Negative

14 (93.3)

11 (73.3)

13 (86.7)

38 (84.4)

DCIS Present (N, %)

 Yes

12 (80.0)

10 (66.7)

9 (60.0)

31 (68.9)

 No

3 (20.0)

5 (33.3)

6 (37.5)

14 (31.1)

Margin Status (N, %)

 Positive (Invasive)

1 (6.7)

1 (6.7)

4 (26.7)

6 (13.3)

 Negative (Invasive)

14 (93.3)

14 (93.3)

11 (73.3)

39 (86.7)

 Positive (DCIS)

1 (6.7)

0 (0.0)

1 (6.7)

2 (4.4)

 Negative (DCIS)

14 (93.3)

15 (100)

14 (93.3)

43 (95.6)

Revised Margins at Index Surgery (N, %)a

 Yes

3 (20.0)

3 (20.0)

4 (26.7)

10 (22.2)

 No

12 (80.0)

12 (80.0)

11 (73.3)

35 (77.8)

Re-excision (N, %)

 Yes

2 (13.3)

1 (6.7)

3 (20.0)

6 (13.3)

 No

13 (86.7)

14 (93.3)

12 (80.0)

39 (86.7)

  1. SD standard deviation, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mammary carcinoma, ER estrogen receptor, PR progesterone receptor, HER2 Human epidermal growth factor receptor 2, DCIS ductal carcinoma in situ
  2. amargin revision not guided by fluorescence imaging